Camurus AB (publ)
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029… Read more
Camurus AB (publ) (CAMRF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.097x
Based on the latest financial reports, Camurus AB (publ) (CAMRF) has a cash flow conversion efficiency ratio of 0.097x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($375.78 Million) by net assets ($3.87 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Camurus AB (publ) - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Camurus AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Camurus AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Camurus AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zabka Group S.A.
WAR:ZAB
|
1.097x |
|
Wuchan Zhongda Group Co Ltd
SHG:600704
|
-0.088x |
|
NBT Bancorp Inc
NASDAQ:NBTB
|
0.042x |
|
WuXi XDC Cayman Inc.
F:L74
|
N/A |
|
Zhejiang Yongtai Technology Co Ltd
SHE:002326
|
0.031x |
|
PennyMac Financial Services Inc
F:1AC
|
-0.166x |
|
Zhejiang Sanmei Chemical Industry Co Ltd
SHG:603379
|
0.081x |
|
Porsche AG
XETRA:P911
|
0.047x |
Annual Cash Flow Conversion Efficiency for Camurus AB (publ) (2014–2024)
The table below shows the annual cash flow conversion efficiency of Camurus AB (publ) from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.29 Billion | $387.99 Million | 0.118x | -70.98% |
| 2023-12-31 | $1.49 Billion | $606.88 Million | 0.406x | +299.53% |
| 2022-12-31 | $994.67 Million | $101.20 Million | 0.102x | +160.22% |
| 2021-12-31 | $848.91 Million | $-143.43 Million | -0.169x | +40.05% |
| 2020-12-31 | $847.44 Million | $-238.83 Million | -0.282x | +55.98% |
| 2019-12-31 | $631.63 Million | $-404.36 Million | -0.640x | +41.06% |
| 2018-12-31 | $252.32 Million | $-274.08 Million | -1.086x | -105.93% |
| 2017-12-31 | $385.00 Million | $-203.08 Million | -0.527x | -43.28% |
| 2016-12-31 | $564.42 Million | $-207.79 Million | -0.368x | -4068.61% |
| 2015-12-31 | $640.56 Million | $-5.66 Million | -0.009x | -101.57% |
| 2014-12-31 | $123.46 Million | $69.43 Million | 0.562x | -- |